Afflovest P
Purchase-Price Allocation
Goodwill
$31.1M
3 years of history · ending 2025-12-31 · SEC EDGAR
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | -7.90% | -1.10% | 4.10% | -23.93% | 5.66% | 6.97% |
| Foreign Rate Differential | — | — | — | — | — | — |
| Other Adjustments | -0.20% | -0.50% | -0.50% | 3.03% | 0.03% | 0.20% |
| R&D Tax Credits | — | — | — | 1.55% | 1.49% | 0.85% |
| Valuation Allowance Change | 8.00% | -5.25% | -37.40% | -84.04% | — | — |
| Tax Settlements (Domestic) | — | — | — | — | — | — |
| Effective Tax Rate | 72.60% | -4.15% | -15.50% | -81.01% | 27.79% | 39.10% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | −$1.6M | $9.5M | $2.4M | −$12.7M | $6.5M | $12.3M |
| Income Taxes Paid (Cash) | — | — | — | $7.4M | $6.9M | $2.5M |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Purchase-Price Allocation
Goodwill
$31.1M
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).